{"count":2329,"next":"https://api-test.medunigraz.at/v1/research/project/?format=json&limit=20&offset=1240&ordering=-end_effective","previous":"https://api-test.medunigraz.at/v1/research/project/?format=json&limit=20&offset=1200&ordering=-end_effective","results":[{"id":3432,"title":{"de":"Prävalenz von invasiven Pilzerkrankungen bei Patienten mit Leberzirrhose","en":"Prevalence of Invasive Fungal Infections in Patients with Liver Cirrhosis "},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2013-12-01T01:00:00+01:00","begin_effective":"2013-12-01T01:00:00+01:00","end_planned":"2015-11-30T01:00:00+01:00","end_effective":"2019-02-19T01:00:00+01:00","assignment":"2013-11-15T12:38:10+01:00","program":null,"subprogram":null,"organization":14046,"category":10,"type":10,"partner_function":4,"manager":54326,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[895],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["3432-50509-12","3432-50715-12","3432-54326-10","3432-76430-12"]},{"id":3809,"title":{"de":"Funktionalität ex vivo generierter Retikulozyten aus humanen Stammzellen","en":"Functional quality of reticulocytes generated ex vivo from human stem cells"},"short":"Ex vivo generated Reticulocytes","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2015-01-01T01:00:00+01:00","begin_effective":"2015-01-01T01:00:00+01:00","end_planned":"2019-02-28T01:00:00+01:00","end_effective":"2019-02-08T01:00:00+01:00","assignment":"2014-11-14T14:34:34+01:00","program":null,"subprogram":null,"organization":14058,"category":10,"type":10,"partner_function":4,"manager":88593,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[1586],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["3809-51164-12","3809-88593-10","3809-93640-12","3809-51910-12","3809-50131-12"]},{"id":4512,"title":{"de":"Kontrolle  des Ansprechens auf neoadjuvante Therapie bei Brustkrebspatientinnen anhand von Plasma-DNA","en":"Clinical utility of plasma-DNA to monitor response to neoadjuvant therapy in breast cancer patients\r\n"},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2016-08-01T02:00:00+02:00","begin_effective":"2016-08-01T02:00:00+02:00","end_planned":"2019-01-31T01:00:00+01:00","end_effective":"2019-01-31T01:00:00+01:00","assignment":"2016-07-11T16:41:21+02:00","program":79,"subprogram":null,"organization":14021,"category":10,"type":10,"partner_function":4,"manager":50899,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[12],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["4512-50899-10"]},{"id":4316,"title":{"de":"Relaxin","en":"Relaxin"},"short":"RELAXIN","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2016-05-01T02:00:00+02:00","begin_effective":"2016-08-01T02:00:00+02:00","end_planned":"2018-04-30T02:00:00+02:00","end_effective":"2019-01-31T01:00:00+01:00","assignment":"2016-02-17T10:16:51+01:00","program":60,"subprogram":null,"organization":14073,"category":10,"type":10,"partner_function":4,"manager":50874,"contact":null,"status":2,"research":3,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":"853276","ethics_committee":null,"edudract_number":null,"persons":["4316-98584-12","4316-50874-10","4316-62756-12","4316-81091-12","4316-108983-12"]},{"id":4256,"title":{"de":"The functional role of HDL in the tumor microenvironment","en":"The functional role of HDL in the tumor microenvironment"},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2015-02-01T01:00:00+01:00","begin_effective":"2015-02-01T01:00:00+01:00","end_planned":"2018-01-31T01:00:00+01:00","end_effective":"2019-01-31T01:00:00+01:00","assignment":"2016-01-28T12:53:45+01:00","program":69,"subprogram":null,"organization":14013,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"J3664-B19","ethics_committee":null,"edudract_number":null,"persons":[]},{"id":3854,"title":{"de":"Die Prävalenz von FHH bei PatientInnen mit einem primären Hyperparathyreoidismus","en":"The Prevalence of FHH in Patients with Primary Hyperparathyroidism"},"short":"EPATH-FHH","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2014-07-01T02:00:00+02:00","begin_effective":"2015-02-01T01:00:00+01:00","end_planned":"2014-02-01T01:00:00+01:00","end_effective":"2019-01-31T01:00:00+01:00","assignment":"2015-01-13T10:13:03+01:00","program":null,"subprogram":null,"organization":14083,"category":10,"type":10,"partner_function":4,"manager":81519,"contact":null,"status":2,"research":4,"grant":10,"event":null,"study":null,"language":null,"funders":[1565],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["3854-81519-10"]},{"id":4928,"title":{"de":"Mikrobiom trifft Plasmidom –  pathogenes Infektionsrisiko, gesunde Mikroorganismen und biologische Vielfalt in einem funktionellen Krankenhaus","en":"Microbiome meets plasmidome – connecting pathogenic infection risk, healthy microbes, and environmental biodiversity in a functional hospital setting"},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2017-02-01T01:00:00+01:00","begin_effective":"2017-02-01T01:00:00+01:00","end_planned":"2019-01-31T01:00:00+01:00","end_effective":"2019-01-31T01:00:00+01:00","assignment":"2017-04-19T11:20:07+02:00","program":null,"subprogram":"START - Med Uni Graz","organization":14046,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[894],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["4928-95317-12","4928-98573-12"]},{"id":3265,"title":{"de":"HOMAGE","en":"HOMAGE"},"short":"HOMAGE","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2012-11-01T01:00:00+01:00","begin_effective":"2013-02-01T01:00:00+01:00","end_planned":"2017-10-30T01:00:00+01:00","end_effective":"2019-01-31T01:00:00+01:00","assignment":"2013-05-13T17:29:05+02:00","program":24,"subprogram":null,"organization":14083,"category":10,"type":10,"partner_function":2,"manager":null,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[10],"funder_projectcode":"305507","ethics_committee":null,"edudract_number":null,"persons":[]},{"id":3413,"title":{"de":"Verhaltensstörungen nach viszeraler Immunaktivierung","en":"Psychopharmacology of the Visceral Immune – Brain Axis"},"short":"Immune-Brain Axis","url":null,"abstract":{"de":"Depression ist eine der häufigsten und schwersten affektiven Störungen, welche die Lebensqualität und Arbeitsfähigkeit der betroffenen Patienten massiv einschränkt und damit von enormer sozio-ökonomischer Bedeutung ist. Die Weltgesundheitsorganisation berichtet, dass Depression in der Altersklasse von 15 – 44 Jahren schon jetzt bei beiden Geschlechtern die zweithäufigste Ursache für „disability adjusted life years“ darstellt und die Zahl der von Depression betroffenen Patienten weiter steigt. Unglücklicherweise sprechen bis zu 40 % der Patienten mit Depression nur unzureichend auf die verfügbaren Antidepressiva an, was mit der Tatsache zusammenhängt, dass die Ätiologie affektiver Störungen nur unvollständig bekannt ist. Abgesehen von genetischen und psychosozialen Risikofaktoren rückt immer mehr auch eine chronische Stimulierung des Immunsystems als eine Ursache für die Entstehung affektiver Störungen in den Blickpunkt. Die Zytokin-Hypothese der Depression postuliert, dass systemische Immunprozesse über erhöhte Blutspiegel proinflammatorischer Zytokine einen Einfluss auf Gehirnfunktionen ausüben, die Ängstlichkeit, Affekt, Stressresistenz und kognitive Prozesse regulieren.\r\nAktivierung des viszeralen Immunsystems und viszerale Entzündung können mit einer Reihe von psychiatrischen Abnormalitäten assoziiert sind. Klinische Beobachtungen sprechen dafür, dass Translokation von Zellwandkomponenten des intestinalen Mikrobioms über eine pathologisch durchlässige Darmschleimhaut zu affektiven Störungen führen kann. Präklinische Befunde belegen, dass gastrointestinale Infektionen, gastrointestinale Entzündungen und intraperitoneale Verabreichung bakteriellen Endotoxins emotional-affektive Verhaltensänderungen auslöst. Vor diesem Hintergrund ist es das Ziel des vorgelegten Projekts, in einem experimentellen Ansatz depressive Verhaltensänderungen nach viszeraler Immunstimulierung in umfassender und innovativer Weise zu analysieren und neue Angriffspunkte für wirksame pharmakologische Interventionen zu identifizieren.\r\nDie wichtigsten Hypothesen, die es zu untersuchen gilt, sind, \r\n•\tdass Zellwandkomponenten des intestinalen Mikrobioms (Lipopolysaccharid, Pepidoglycan) und  intestinale Hormone unter dem Einfluss des Mikrobioms (Glucagon-Like Peptide, Peptid YY) depressive Verhaltensänderungen hervorrufen,\r\n•\tviszerale Immunaktivierung das affektive Verhalten kurz- und langfristig beeinflusst;\r\n•\tspezifische Signaltransduktionsmechanismen im Gehirn (Receptor-Activator of Nuclear Factor B Ligand, Cyclooxygenase-2 und Brain-Derived Neurotrophic Factor) von Relevanz für die affektiven Störungen im Gefolge einer peripheren Immunaktivierung sind, und\r\n•\tdepressive Verhaltensänderungen nach viszeraler Immunstimulierung mit einer Störung der Hypothalamus-Hypophysen-Nebennieren-Achse, einer Störung des Glukokortikoid-Feedback an das Gehirn und einer Störung der Neurogenese im limbischen System assoziiert sind.","en":"Being one of the most prevalent and severe mood disorders, major depression is deleterious to the patients’ quality of life and of enormous socio-economic impact. According to the World Health Organization, depression is the second most frequent cause of disability-adjusted life years in the age category of 15 – 44 years for both genders, with the number of patients continuing to grow. A proportion of some 40 % of the patients does not satisfactorily respond to the available antidepressant drugs, which reflects the incomplete understanding of the aetiology of affective disorders. Apart from vulnerability and psychosocial factors, chronic immune challenge has emerged as a circumstance relevant to the pathogenesis of mood disorders. The cytokine hypothesis of depression holds that systemic inflammatory processes associated with elevated levels of circulating proinflammatory cytokines disturb several brain mechanisms that control anxiety, mood, stress resilience and cognition.\r\nVisceral immune activation and inflammation are associated with a variety of psychiatric abnormalities, and there is clinical evidence that constituents of the intestinal microbiota across a leaky mucosal barrier may be a factor underlying mood disorders. Preclinical evidence indicates that gastrointestinal infection and inflammation as well as intraperitoneal administration of bacterial lipopolysaccharide induce behavioural disturbances. The current research proposal sets out to specifically examine the visceral immune – brain axis in an innovative and comprehensive manner and to identify key mechanisms that are suitable for pharmacological modulation.\r\nThe main hypotheses to be addressed are that\r\n•\tfactors derived from the intestinal microbiota (lipopolysaccharide, pepidoglycan) or intestinal hormones under the regulatory influence of the microbiota (glucagon-like peptide, peptide YY) have an impact on the visceral immune – brain axis;\r\n•\tvisceral immune challenge has a short- and long-term impact on affective behaviour;\r\n•\tspecific brain signalling mechanisms involving receptor-activator of nuclear factor B ligand,  cyclooxygenase-2 and brain-derived neurotrophic factor play a role in the behavioural effects of peripheral immune challenge; and\r\n•\tactivation of the visceral immune – brain axis is associated with deranged activity of the hypothalamic-pituitary-adrenal axis, disturbed glucocorticoid feedback on the brain and altered neurogenesis in the limbic system."},"begin_planned":"2013-10-01T02:00:00+02:00","begin_effective":"2014-02-01T01:00:00+01:00","end_planned":"2016-09-30T02:00:00+02:00","end_effective":"2019-01-31T01:00:00+01:00","assignment":"2013-10-25T11:06:48+02:00","program":72,"subprogram":null,"organization":14022,"category":10,"type":10,"partner_function":4,"manager":51529,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"P25912","ethics_committee":null,"edudract_number":null,"persons":["3413-71386-12","3413-71487-12","3413-77692-12","3413-51529-10"]},{"id":3738,"title":{"de":"Potentielle positive Effekte von intestinaler ATGL Überexpression","en":"Potential beneficial effects of intestinal ATGL overexpression"},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2015-01-01T01:00:00+01:00","begin_effective":"2015-01-01T01:00:00+01:00","end_planned":"2017-12-31T01:00:00+01:00","end_effective":"2019-01-31T01:00:00+01:00","assignment":"2014-08-07T12:28:43+02:00","program":72,"subprogram":null,"organization":14013,"category":10,"type":10,"partner_function":4,"manager":51904,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"P 27070","ethics_committee":null,"edudract_number":null,"persons":["3738-51904-10"]},{"id":3852,"title":{"de":"Aufklärung der spezifischen Zytotoxizität von Dimethylacrylshikonin in Melanomzellen","en":"Elucidation of specific cytotoxic effects of dimethylacrylshikonin in melanoma cells"},"short":"SpeDiMel","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2015-01-01T01:00:00+01:00","begin_effective":"2015-01-28T01:00:00+01:00","end_planned":"2018-01-01T01:00:00+01:00","end_effective":"2019-01-27T01:00:00+01:00","assignment":"2015-01-09T09:19:54+01:00","program":72,"subprogram":null,"organization":17218,"category":10,"type":10,"partner_function":2,"manager":50826,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"P27505","ethics_committee":null,"edudract_number":null,"persons":["3852-50826-10"]},{"id":4221,"title":{"de":"Standardisation of a novel method to measure subcutaneous fat in athletes in sports medicine","en":"Standardisation of a novel method to measure subcutaneous fat in athletes in sports medicine"},"short":"IOC-BCHP","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2015-07-01T02:00:00+02:00","begin_effective":"2015-07-01T02:00:00+02:00","end_planned":"2016-12-31T01:00:00+01:00","end_effective":"2018-12-31T01:00:00+01:00","assignment":"2016-01-12T11:45:14+01:00","program":null,"subprogram":null,"organization":14011,"category":10,"type":10,"partner_function":3,"manager":null,"contact":null,"status":2,"research":3,"grant":10,"event":null,"study":null,"language":null,"funders":[],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":[]},{"id":4247,"title":{"de":"1.2 -Innovative Nutzung von Information für klinische Versorgung und Biomarkerforschung - CBmed","en":"1.2 - Innovative Use of Information for Clinical Care and Biomarker Research - CBmed"},"short":"IICCAB (CBmed 1.2)","url":null,"abstract":{"de":"Im Projekt CBmed 1.2, genannt IICCAB (Innovative Nutzung von Information für klinische Versorgung und Biomarkerforschung) werden im ersten Schritt bis 2018 im großen Maßstab klinische Daten zur besseren Weiterverwendung aufgearbeitet, um dann in vier unterschiedliche Pilotanwendungen einzufließen. \r\n\r\nDaten für Biomarkerforschung kommen aus nicht nur aus Speziallabors, sondern auch aus unterschiedlichsten Quellen, in denen klinischen Routinedaten abgelegt sind. Die Fusionierung dieser Daten erfordert eine automatische begriffliche Normierung, um sie zu aggregieren und so für innovative Anwendungen verfügbar zu machen. Den Kern des Systems bildet eine Hochleistungs-Datenbank, die die SAP-HANA-Technologie nutzt. Da ein wichtiger Teil der klinischen Informationen ausschließlich als Text vorliegt, muss dieser mit Hilfe von sprachtechnologischen Verfahren analysiert und auf ein standardisiertes Vokabular abgebildet werden. Die so gewonnenen Daten ermöglichen gemeinsam mit den bereits strukturiert vorliegenden Daten wie Laborparameter, Diagnosencodes usw. semantisch genormte Patientenprofile, mit denen in der ersten Phase von IICCAB vier Pilotanwendungen unterstützt werden.\r\n\r\nDie aufbereiteten Daten bilden die Grundlage für vier verschiedene Anwendungsszenarien: Das Szenario \"Recruiting\" wird es erleichtern, mit Hilfe graphischer Recherchewerkzeuge Patientengruppen anhand vielfältiger Merkmale zu definieren. Dies ist eine entscheidende Voraussetzung für Forschungsvorhaben aller Art, beispielsweise in der Biomarkerforschung.   \r\nDas Szenario \"Prediction\" wurde entwickelt, um anhand von semantisch angereicherten Patientenprofilen Vorhersagen zu künftigen Ereignissen, wie etwa Wiederaufnahmen, zu treffen. Die Anwendung \"Patient Quick View\" stellt eine automatische Zusammenfassung entscheidungsrelevanter Patientendaten zur Verfügung, abhängig von den Präferenzen der jeweiligen Nutzergruppe und Arbeitssituation. Damit wird eine Alternative geschaffen zum zeitaufwändigen Recherchieren in elektronischen Patientenakten. Die Anwendung \"Coding\" unterstützt Ärztinnen und Ärzte bei der Kodierung von Krankheitsfällen für administrative Zwecke, indem IICCAB die verfügbaren Daten analysiert und den Nutzern Vorschläge für passende Diagnosen- und Prozeduren-Codes unterbreitet. \r\n\r\nDie erste Phase des vom Bund (FFG) geförderten IICCAB – Projekts innerhalb des österreichischen Kompetenzzentrums für Biomarkerforschung (CBMed - http://www.cbmed.org/de/) läuft bis Ende 2018 und wird von Stefan Schulz, Universitätsprofessor für Medizininformatik an der Medizinischen Universität Graz, geleitet. Kooperationspartner sind die Steiermärkischen Krankenanstaltengesellschaft m.b.H. (KAGes), die Med Uni Graz mit der Biobank, sowie die Softwarefirma SAP.\r\n","en":"In Project 1.2 CBmed, called IICCAB (Innovative Use of Information for Clinical Care and Biomarker Research) large-scale clinical data sets are processed for better re-use. \r\n\r\nData for biomarker research come not only from specialized laboratories but also from different sources, in which routine clinical data are stored. The merging of these data requires automatic semantic normalization in order to aggregate them and to make them available for innovative applications. \r\nThe core of the system developed by IICCAB is a high performance database, which uses SAP HANA technology. Since an important part of clinical information is found exclusively as narratives within free-text fields of clinical databases, human language technology methods are required to analyse this content and to map it to a standardized vocabulary. The data obtained allow, together with already available structured data like lab parameters, disease codes, etc. semantically standardized patient profiles.  \r\n\r\nThe processed data is the basis for four different application scenarios: \r\n\r\n1. \"Recruiting\" will facilitate patient cohorts in terms of various characteristics, using advanced graphical interfaces for querying and visualization. This is a crucial prerequisite for all kinds of clinical research, especially regarding biomarkers and the use of biosamples.\r\n\r\n2. \"Prediction\" will focus on predictive analytics based on semantically enriched patient profiles, in order to help estimate the probability of future events, such as hospital re-admissions. \r\n\r\n3. \"Patient QuickView\" will provide an automatic summary of decision-relevant patient data, depending on the preferences of each user group and task. Thus, an alternative is provided for time-consuming browsing through numerous documents in electronic health records. \r\n\r\n4. \"Coding\" supports physicians in the coding of disease cases for administrative purposes.  IICCAB analyses available clinical data and proposes appropriate disease and procedure codes.\r\n\r\nIn the first phase of IICCAB (2016 – 2018), funded by FFG, CBmed cooperates with the Styrian Hospital Association (KAGes), the Institute of Medical Informatics, Statistics and Documentation of the Medical University of Graz, the Biobank Graz, and the German software company SAP under the lead of Stefan Schulz, university professor of medical informatics at the Medical University of Graz. "},"begin_planned":"2015-07-01T02:00:00+02:00","begin_effective":"2015-07-01T02:00:00+02:00","end_planned":"2018-12-31T01:00:00+01:00","end_effective":"2018-12-31T01:00:00+01:00","assignment":"2016-01-26T11:59:41+01:00","program":94,"subprogram":null,"organization":14026,"category":10,"type":10,"partner_function":4,"manager":72306,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["4247-72306-10"]},{"id":6060,"title":{"de":"ADOPT BBMR-ERIC ","en":"ADOPT BBMR-ERIC "},"short":"Adopt","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2017-01-01T01:00:00+01:00","begin_effective":"2017-01-01T01:00:00+01:00","end_planned":"2018-12-31T01:00:00+01:00","end_effective":"2018-12-31T01:00:00+01:00","assignment":"2020-02-19T16:43:59+01:00","program":109,"subprogram":null,"organization":28392,"category":10,"type":10,"partner_function":2,"manager":58453,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[10],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["6060-58453-10"]},{"id":3915,"title":{"de":"Dysregulation von extrazellulärer Matrix in verschiedenen Formen pulmonaler Hypertonie","en":"Extracellular matrix dysregulation in different forms of pulmonary hypertension "},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2014-07-01T02:00:00+02:00","begin_effective":"2015-03-01T01:00:00+01:00","end_planned":"2017-06-30T02:00:00+02:00","end_effective":"2018-12-31T01:00:00+01:00","assignment":"2015-02-26T14:23:51+01:00","program":79,"subprogram":null,"organization":14010,"category":10,"type":10,"partner_function":4,"manager":82090,"contact":null,"status":2,"research":5,"grant":10,"event":null,"study":null,"language":null,"funders":[12],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["3915-61540-12","3915-82090-10"]},{"id":4164,"title":{"de":"Regulation der Eosinophilen Funktion durch kurzkettige Fettsäuren und deren Rezeptoren FFA2 und FFA3","en":"Regulation of eosinophil function by short chain fatty acids and their receptors FFA2 and FFA3"},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2016-01-01T01:00:00+01:00","begin_effective":"2016-01-01T01:00:00+01:00","end_planned":"2018-12-31T01:00:00+01:00","end_effective":"2018-12-31T01:00:00+01:00","assignment":"2015-11-23T12:06:05+01:00","program":null,"subprogram":null,"organization":14022,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[15],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":[]},{"id":4243,"title":{"de":"Synthese licht-aktiver Modulatoren/Marker von TRPC3/6-Kanälen","en":"Synthesis of light-responsive modulators/labels of TRPC3/6-channels"},"short":null,"url":null,"abstract":{"de":null,"en":"Novel light-responsive modulators/labels of TRPC3/6-channels\r\nMammalian Transient Receptor Potential (TRP) channels include six related protein\r\nfamilies. Members of the human TRP Canonical (TRPC) subfamily\r\n(TRPC1/3/4/5/6/7), form channels that mediate Ca2+- and Na+-ion entry and are\r\nexpressed in many mammalian cell types to serve a broad-range of important\r\nphysiological processes. Recently, TRPC3/6 channels have been implicated in the\r\npathogenesis of cardiovascular disorders including heart failure, arrhythmias, and\r\nsudden death. Consequently, TRPC channels have emerged as highly promising\r\ntargets for drug development, while, at the same time, their exact cellular function and\r\nprinciples of pharmacologic modulation are still incompletely understood and require\r\nbetter understanding. For this, novel strategies to experimentally control channel\r\nfunction are urgently needed. These channels are endogenously controlled by plasma\r\nmembrane lipid metabolites, which are difficult to administer in most experimental\r\nsettings. Novel modulating or blocking ligands with potentially suitable selectivity for\r\nexact experimental control of TRPC3/6 channel have just recently been reported. One\r\nobjective of this proposal is therefore the synthesis of small modulators\r\n(inhibitors/activators) of TRPC3/6-channels that response to light, allowing the\r\ncontrol of biological events with unparalleled spatial and temporal precision – so\r\ncalled “photoswitches” (e.g. azobenzens). Taking advantage of our experience in the\r\nsynthesis of pyrazole-based inhibitors of TRPC3/6-channels and benzimidazolonebased\r\nactivators as well as our expertise in microwave and continuous-flow\r\nchemistry, we aim to generate and explore various photoswitchable ligands in\r\nconnection to the emerging pharmacology of TRPC3/6-channels. Another objective\r\nof ours, involving small photoresponsive molecules, is the synthesis of photoaffinity\r\nlabels to help in the elucidation of potential ligand-binding sites in the TRPC3/6-\r\nchannels as well as on the structure elucidation of TRPC3/6-channels.\r\nThe research proposed herein is meant to become a significant contribution to\r\na thrilling and rapidly growing field for optoregulation of biological functions in\r\nmammalian cells and for better understanding on the TRPC3/6-channel machinery. If\r\npositive results are obtained, the arising pharmacology will importantly aid\r\ninvestigations of the physiological and pathophysiological roles of TRPC channels,\r\nfacilitate the validation of TRPCs as potential therapeutic targets in different\r\nchannelopathies, and possibly provide foundations for drug discovery and\r\ndevelopment."},"begin_planned":"2015-05-01T02:00:00+02:00","begin_effective":"2015-05-01T02:00:00+02:00","end_planned":"2018-04-30T02:00:00+02:00","end_effective":"2018-12-31T01:00:00+01:00","assignment":"2016-01-22T13:09:43+01:00","program":72,"subprogram":null,"organization":14011,"category":10,"type":10,"partner_function":2,"manager":78591,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"P 28243-B27   ","ethics_committee":null,"edudract_number":null,"persons":["4243-78591-10"]},{"id":5014,"title":{"de":"Forschungen zu Infektionserkrankungen bei Kindern im Rahmen der Projekte\r\n„EU-TICK.BO“, „RNA-Sequenzierung bei akuter Faszialisparese“ sowie „Beschreibung des\r\nMasernausbruches 2017“","en":"EU-Tick-BO, RNA sequencing in acute facial palsy, and measles outbreak in Styria"},"short":"Eutickbo","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2017-07-01T02:00:00+02:00","begin_effective":"2017-07-01T02:00:00+02:00","end_planned":"2018-06-30T02:00:00+02:00","end_effective":"2018-12-31T01:00:00+01:00","assignment":"2017-07-17T12:39:38+02:00","program":null,"subprogram":null,"organization":14091,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":[]},{"id":4491,"title":{"de":"Early Detection of Trastuzumab induced Cardiotoxicity with novel Biomarkers and Identification of protective Co-treatments","en":"Early Detection of Trastuzumab induced Cardiotoxicity with novel Biomarkers and Identification of protective Co-treatments"},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2016-06-01T02:00:00+02:00","begin_effective":"2016-06-01T02:00:00+02:00","end_planned":"2017-12-31T01:00:00+01:00","end_effective":"2018-12-31T01:00:00+01:00","assignment":"2016-06-15T14:41:57+02:00","program":null,"subprogram":null,"organization":14083,"category":10,"type":10,"partner_function":4,"manager":58906,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[140],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["4491-96882-12","4491-58906-10"]},{"id":3647,"title":{"de":"Vascular endothelial dysfunction: The putative interface of emerging cardiovascular risk factors affecting populations living with and without HIV in Sub-Saharan Africa","en":"Vascular endothelial dysfunction: The putative interface of emerging cardiovascular risk factors affecting populations living with and without HIV in Sub-Saharan Africa"},"short":"ENDOAFRICA","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2014-06-01T02:00:00+02:00","begin_effective":"2014-04-01T02:00:00+02:00","end_planned":"2016-05-31T02:00:00+02:00","end_effective":"2018-12-31T01:00:00+01:00","assignment":"2014-04-30T16:02:52+02:00","program":null,"subprogram":"ERAFRICA","organization":14010,"category":10,"type":10,"partner_function":4,"manager":57932,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[20],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["3647-50514-12","3647-57932-10","3647-51812-12"]}]}